Patrick Shenot, MD
Urology · Philadelphia, PANPI 1740209493
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Merck at 54.4% of the total. Reporting peaked in 2023 at $2,097 and has fallen 66.4% since, to $705 in 2025.
Across 115 payments — averaging $93.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$6K
- Medtronic$2K
- Coloplast$2K
- 180 Medical, Inc.$252
- Sumitomo Pharma America, Inc.$172
- Tolmar, Inc.$163
- plus $952 from 19 others
Across 22 payments — averaging $6714.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$144K
- Ipsen Innovation$4K
What the payments were for
- Consulting fees$5,87554%
- Speaking & faculty fees$150%
- Travel & lodging$1,21611%
- Food & beverage$3,66734%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 6 | $5,875 |
| Medtronic(2 entities) | 41 | $1,806 |
| Coloplast | 18 | $1,588 |
| 180 Medical, Inc. | 5 | $252 |
| Sumitomo Pharma America, Inc. | 7 | $172 |
| Tolmar, Inc. | 1 | $163 |
| Myriad Genetic Laboratories, Inc. | 3 | $137 |
| Johnson & Johnson | 5 | $118 |
| Boston Scientific | 5 | $93 |
| Bluewind Medical | 2 | $62 |
| AbbVie | 3 | $61 |
| Urogen Pharma, Inc. | 2 | $60 |
| Smith+Nephew | 2 | $59 |
| Teleflex LLC | 2 | $59 |
| Astellas Pharma US Inc | 2 | $44 |
| ABC Home Medical Supply, Inc. | 1 | $37 |
| AstraZeneca | 1 | $35 |
| Calyxo, Inc. | 2 | $35 |
| Corcept Therapeutics | 1 | $29 |
| Progenics Pharmaceuticals, Inc. | 1 | $29 |
| Novartis | 1 | $25 |
| Bayer | 1 | $23 |
| Hollister Incorporated | 1 | $20 |
| BD | 1 | $15 |
| Avation Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,808 in reported general payments places this provider in the 85th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 201 | $139,617 |
| GemtesaVibegron | 34 | $25,191 |
| Tamsulosin Hcl | 333 | $8,432 |
| Trospium Chloride ErTrospium Chloride | 17 | $5,237 |
| Solifenacin Succinate | 58 | $4,469 |
| Oxybutynin Chloride ErOxybutynin Chloride | 109 | $3,938 |
| Oxybutynin Chloride | 85 | $2,565 |
| Finasteride | 98 | $1,960 |
| Dutasteride | 44 | $1,845 |
| Methenamine Hippurate | 20 | $1,760 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 61 | $1,607 |
| Tadalafil | 56 | $1,527 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 48 | $1,296 |
| Silodosin | 16 | $1,186 |
| Imipramine Hcl | 13 | $814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $44 | $139,617201 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $172 | $25,19134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 596 urology providers in Pennsylvania.
Other urology in Philadelphia
- Demetrius BagleyPhiladelphia$739K
- Daniel EunPhiladelphia$226K
- Leonard GomellaPhiladelphia$190K
- Phillip GinsbergPhiladelphia$145K
- Edouard TrabulsiPhiladelphia$137K
- Siobhan HartiganPhiladelphia$121K
- Paul ChungPhiladelphia$120K
- William JaffePhiladelphia$119K
- Robert UzzoPhiladelphia$111K
- Jay SimhanPhiladelphia$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.